ADMA
"Culper Research alleges ADMA fabricated 20% revenue growth while actual sales declined 3% -- with $510M in reported revenue, 73% customer concentration, and a $200M buyback amid securities fraud investigations, is ASCENIV's 51% growth real or engineered?"
ADMA Biologics is a plasma-derived therapeutics company whose specialty IVIG product ASCENIV commands 5.5-6x the price of standard immune globulin. The company reported $510M in FY2025 revenue with 20% growth, driven by ASCENIV's 51% year-over-year increase to $363M. In early 2026, Culper Research published a short report alleging channel stuffing, undisclosed related-party sales, and fabricated revenue growth, triggering a 29% stock crash and multiple securities fraud investigations. ADMA disputes all allegations, has maintained its $635M+ FY2026 revenue guidance, and is executing a $200M share repurchase program with $125M accelerated.
Executive Summary
Cross-lens roll-up assessment
ADMA Biologics presents one of the most challenging analytical cases in 2026: a company with verifiably strong product-level growth (ASCENIV at 51% YoY) that simultaneously exhibits the working capital patterns short sellers cite as red flags. The committee's 5-lens analysis finds that the core revenue growth is likely real -- ASCENIV's differentiation, clinical data, and pricing power are well-documented in SEC filings. However, the extreme customer concentration (73% of revenue from 2 customers, 87% of AR), rising DSO, and CFO departure create legitimate questions about the pace and quality of reported growth. The short seller allegations appear to overstate the case (a -3% revenue decline is inconsistent with the disclosed ASCENIV revenue of $363M), but the underlying concerns about working capital efficiency and channel dynamics warrant elevated scrutiny.
HIGHER_SCRUTINY reflects genuine uncertainty that cannot be resolved until Q1/Q2 2026 financial data demonstrates whether DSO normalizes and channel inventory clears. The core product (ASCENIV) appears to have real clinical differentiation and demand, and the short seller's claim of -3% revenue decline conflicts with audited product-level data. However, the extreme customer concentration, rising accounts receivable, CFO departure, and multiple concurrent investigations create a risk profile that demands closer monitoring than standard diligence. The committee does not find evidence sufficient to classify this as AVOID, but the unresolved working capital concerns preclude PROCEED_WITH_CAUTION.
Key Takeaways
- •ACCOUNTING_INTEGRITY is QUESTIONABLE: The core allegation of fabricated revenue growth appears overstated -- ASCENIV product-level revenue of $363M is newly disclosed and audited by KPMG. However, extreme AR concentration (87% from 2 customers) and management's own acknowledgment of elevated DSO create a legitimate basis for scrutiny of revenue timing and channel health.
- •REVENUE_DURABILITY is CONDITIONAL: ASCENIV's 51% growth and 5.5-6x pricing premium over standard IVIG represent genuine product differentiation backed by published clinical data. Revenue durability depends on whether channel inventory normalizes in 2026 and whether the McKesson distribution agreement diversifies the customer base as management projects.
- •GOVERNANCE_ALIGNMENT is MIXED: CEO Grossman is a net buyer of shares (+98,927 net shares, 10b5-1 plan in place), which conflicts with the short seller narrative. However, Director Steve Elms proposed a $9.3M sale, and the CFO departed during peak controversy. The $200M buyback ($125M accelerated) could signal confidence or an attempt to support the stock price.
- •NARRATIVE_REALITY_GAP is WIDE: The gap between the short seller thesis (-3% revenue decline, channel stuffing) and management's thesis ($635M+ guidance, 51% ASCENIV growth) is among the widest we have measured. Resolution depends on Q1/Q2 2026 DSO trends and channel inventory normalization.
- •FUNDING_FRAGILITY is STABLE: $88M cash with positive adjusted net income ($161M) provides adequate runway. The company is now profitable on an adjusted basis. Debt structure and covenants do not appear at immediate risk.
Key Tensions
- •ASCENIV's 51% product growth is audited and real, but 73% revenue concentration through 2 distributors means that inventory build in the channel could inflate reported revenue without corresponding end-patient demand -- the channel stuffing claim cannot be fully disproven until DSO normalizes
- •CEO Grossman's net buying pattern contradicts the fraud narrative, but the departing CFO and the timing of the new CFO hire (specialist in 'working capital optimization') suggest management itself recognizes the AR/DSO problem is material
- •The $200M buyback at depressed prices ($125M accelerated) could be value-maximizing if the business is sound, or capital destruction if the short seller is even partially correct about revenue quality
Fugazi Filter
Are the numbers trustworthy?
Dual-Axis Risk Classification
Position shows Accounting Integrity × Funding Fragility
No elevated red flags detected. Standard investment analysis practices apply — focus on valuation and business fundamentals.
Key FindingsClick to expand details
Signal AssessmentsClick for full context
| Signal | Scale | Assessment | Evidence |
|---|---|---|---|
Accounting Integrity | — | QUESTIONABLE | 2Corroborated |
Governance Alignment | — | MIXED | 2Corroborated |
Model Debates
Cross-Lens Insights
Where Lenses Agree
- ASCENIV's clinical differentiation and pricing power are real, not fabricated
- The AR/DSO concern is legitimate even if the fraud allegation is overstated
- CEO insider accumulation is the strongest signal against the fraud narrative
Where Lenses Differ
ACCOUNTING_INTEGRITY
The Fugazi Filter flags the AR concentration pattern as QUESTIONABLE from an accounting perspective, while the Revenue Revealer finds the underlying product revenue credible. Both can be true -- the accounting methodology may be correct (revenue properly recognized under ASC 606) while the commercial outcome (channel sell-through) remains uncertain.
The following publicly available documents were collected and extracted into a structured fact dossier that powered this analysis.
SEC Filing
- Annual Report (10-K) -- FY2025
- Quarterly Report (10-Q) -- Q3 2025
- Quarterly Report (10-Q) -- Q2 2025
- Quarterly Report (10-Q) -- Q1 2025
- Quarterly Report (10-Q) -- Q3 2024
- Current Reports (8-K) -- 10 filings, Mar 2025 - Mar 2026
- Form 4 Insider Transactions -- 20 filings
- Form 144 Proposed Sales -- 10 filings
Earnings Transcript
- Q4 2025 Earnings Call Transcript
- Q3 2025 Earnings Call Transcript
- Q2 2025 Earnings Call Transcript
- Q1 2025 Earnings Call Transcript
Research Document
- CourtListener Litigation Search -- 10 cases